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Purpose: To evaluate changes in clinical outcomes, inflammatory cytokine levels, 
and tear osmolarity in the tears of patients with moderate to severe dry eye syn-
drome before and after the application of topical 1% methylprednisolone. Materi-
als and Methods: Thirty-two patients with moderate to severe dry eye unrespon-
sive to previous aqueous enhancement therapy were enrolled. Five patients were 
lost to follow up, and twenty-seven patients were eligible for analysis. Patients 
were instructed to apply topical 1% methylprednisolone four times per day, as well 
as to continue applying their current therapy of preservative-free 0.1% sodium hy-
aluronate four times per day. Corneal and conjunctival staining scores, tear film 
breakup time (TFBUT), Schirmer test, and tear osmolarity were assessed at base-
line, 4 weeks, and 8 weeks. Tear samples were collected at every visit for cytokine 
analysis. Results: Corneal and conjunctival staining scores and TFBUT showed 
significant improvement at 4 (p<0.001, <0.001, <0.001 respectively) and 8 
(p<0.001, <0.001, <0.001 respectively) weeks. Tear osmolarity decreased signifi-
cantly at 8 weeks (p=0.008). Interleukin (IL)-1β, IL-8, and monocyte chemoattrac-
tant protein-1 were significantly decreased at 8 weeks compared with those at 
baseline (p=0.041, 0.001, 0.008 respectively). Conclusion: Short-term treatment 
with topical 1% methylprednisolone not only improved clinical outcomes, but also 
decreased tear osmolarity and cytokine levels. By measuring the changes in cyto-
kine levels and tear osmolarity, we could objectively evaluate the anti-inflammato-
ry effects of topical methylprednisolone applied in the treatment of patients with 
moderate to severe dry eye syndrome.
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nisolone
INTRODUCTION
Dry eye syndrome is a common condition that affects approximately 10-20% of 
the adult population.1 The disease is associated with subjective symptoms, objec-
tive signs, including tear film instability, and ocular surface inflammation.2,3
While the pathogenesis of dry eye syndrome has not been clearly established, 
there is increasing evidence that ocular surface inflammation plays a key role. In-
creased levels of osmolarity and inflammatory cytokines have been detected in the 
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Review Board of Severance Hospital and conducted ac-
cording to the Declaration of Helsinki and Good Clinical 
Practices. Informed consent was obtained from all patients.
Study design
This study was designed as a prospective study. Patients 
were instructed to apply a drop of topical 1% methylpred-
nisolone four times per day at six-hour intervals in addition 
to continuing their previous aqueous enhancement therapy 
for 8 weeks, which consisted of applying preservative-free 
0.1% sodium hyaluronate four times per day. All of the fol-
lowing parameters were evaluated at baseline, 4 weeks, and 
8 weeks: fluorescein corneal and conjunctival staining, TF-
BUT, Schirmer test, tear osmolarity, and tear collection for 
cytokine analysis. To minimize the effect of other examina-
tions, tear osmolarity was measured first and Schirmer test 
was performed last. 
Study material
Topical methylprednisolone was prepared by diluting intra-
venous methylprednisolone sodium succinate (Solu-me-
drol®, Pfizer, New York, NY, USA) in non-preserved sterile 
normal saline at a final concentration of 1%.10 
Clinical assessment 
Corneal staining
The degree of staining was measured for each of the five 
regions of the cornea: central, superior, temporal, nasal, and 
inferior. The degree of staining was based on the following: 
grade 0 (normal), no staining; grade 1 (mild), superficial 
stippling and micropunctate staining; grade 2 (moderate), 
macropunctate staining with some coalescent areas; and 
grade 3 (severe), numerous coalescent macropunctate areas 
and/or patches. Each of the five regions was graded on a 
scale from 0 to 3. The scores of the five areas were added to 
obtain a total score for each eye.
Conjunctival staining
The degree of staining was separately assessed for the three 
portions of the temporal conjunctiva and the three portions 
of the nasal conjunctiva on a scale from 0 to 3. The scores 
for each of the six areas were added to obtain a total score 
for each eye.
TFBUT and Schirmer test
Fluorescein strip was wet with a drop-volume of non-pre-
tears of dry eye patients,4-8 and immunopathological chang-
es have also been detected in the conjunctiva of patients 
with dry eye syndrome.9
Clinical evidence has shown that topical anti-inflamma-
tory treatments are effective in the treatment of dry eye syn-
drome.10-12 Topical methylprednisolone has been reported to 
reduce the levels of inflammatory cytokines in experimen-
tal murine dry eyes.13 
Although previous studies have confirmed that the tears 
of dry eye syndrome patients have increased inflammatory 
cytokine levels and osmolarity,4-8 few studies have investi-
gated changes in inflammatory cytokine levels and tear os-
molarity before and after treatment.14,15 Byun, et al.14 mea-
sured changes in proinflammatory cytokines, interleukin 
(IL)-6, and IL-8, to compare the efficacy of the combined 
use of methylprednisolone and topical cyclosporine with 
the use of topical cyclosporine alone. Tear osmolarity mea-
sured using a TearLab osmometer showed significant reduc-
tions in all groups treated with different artificial tears.15 In 
this study, we performed an analysis of multiple cytokines 
including IL-6 and IL-8 using immunobead assay, and si-
multaneously measured changes in tear osmolarity after 
treatment with topical corticosteroid.  
The aim of this study was to evaluate changes in clinical 
outcomes, levels of inflammatory cytokines, and tear osmo-
larity in patients with dry eye syndrome after treatment 
with topical 1% methylprednisolone. 
MATERIALS AND METHODS
　　　
Patient selection 
Thirty-two patients with moderate to severe dry eye syn-
drome whose signs and symptoms were unresponsive to 
previous aqueous enhancement therapy with 0.1% sodium 
hyaluronate for 8 weeks were enrolled in this study. Inclu-
sion criteria were as follows: tear film breakup time (TF-
BUT) less than 5 seconds, Schirmer I test less than 5 mm, 
and positive corneal and conjunctival staining. Exclusion 
criteria included any evidence of acute or chronic infection, 
any inflammatory condition of the cornea and conjunctiva 
other than dry eye syndrome, history of ocular surgery, use 
of contact lenses, use of other topical ocular medications, 
history of known collagen vascular disease such as patients 
with secondary Sjögren syndrome or positive serology of 
autoantibodies, and history of adverse events to the study 
medication. The study was approved by the Institutional 
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Biosciences, San Jose, CA, USA). The cytokines and che-
mokines that were analyzed included IL-1β, IL-6, IL-17, 
interferon gamma (IFN-γ), tumor necrosis factor (TNF)-α, 
IL-8, and monocyte chemotactic protein-1 (MCP-1). 
Safety monitoring 
All possible adverse events were assessed at every visit. Pa-
tients were also encouraged to report any unintended symp-
toms or signs.
Statistical analysis
Changes in clinical parameters, tear osmolarity, and cyto-
kine levels were compared using a paired t-test. All statisti-
cal analyses were performed using SPSS version 12.0 (SPSS 
Inc., Chicago, IL, USA). 
 
RESULTS
 
Patients
Thirty-two patients were enrolled in this study; five patients 
were lost to follow up after their baseline visit. Twenty-sev-
en patients who completed the study were eligible for anal-
ysis (22 females, 5 males; mean age±standard deviation 
53.85±13.14, range from 27 to 73 years). 
Mean tear osmolarity at baseline (308.95±17.64 mOsm/
L) was similar to that found by Suzuki, et al.7 (309.7±22.3 
mOsm/L) (Table 1), and seven cytokines were detected 
(Table 2).
served saline solution and the strip was touched to the infe-
rior palpebral conjunctiva. Patients were asked to blink sev-
eral times. The investigator monitored the integrity of the 
tear film with a slit lamp and measured up to the time until 
one or more dry spots appeared in the precorneal tear film 
from the last blink. Schirmer I test with topical anesthesia 
was performed to evaluate basal tear secretion. 
Tear osmolarity 
Tear osmolarity was measured using a handheld TearLabTM 
device (TearLab Co., San Diego, CA, USA). A 50-nL tear 
sample was obtained from the inferior tear lake near the lat-
eral canthus.
Tear collection and multiplex immunobead assay 
Thirty μL of phosphate-buffered saline was instilled into the 
conjunctival sac, and patients were instructed to blink slightly 
once. A 20-μL volume of tear fluid and buffer were collected 
with a micropipette at the lateral canthus, avoiding any addi-
tional tear reflex. During collection of tear fluid, patients 
were instructed not to blink and to keep looking up to avoid 
damage to the corneal epithelium. The fluid was placed into 
a 1.5 mL Eppendorf tube and the tube was vortexed briefly to 
reduce the adherence of tear proteins to the sides of tube, 
which was stored at -70°C until further examination.
Cytokine concentrations were measured using both mul-
tiplex immunobead assay (BDTM Cytometric Bead Array 
Human Soluble Protein Flex Set, BD Biosciences, San Jose, 
CA, USA) and flow cytometry (BDTM FACS LSR II, BD 
Table 1. Changes in Dry Eye Signs and Tear Osmolarity
Baseline (SE) 4 wks (SE) p value 8 wks (SE) p value
Corneal staining score   10.24 (1.00)     5.47 (0.80) <0.001     3.18 (0.55) <0.001
Conjunctival staining score     9.04 (0.66)     5.63 (0.91) <0.001     2.52 (0.74) <0.001
TFBUT (sec)     3.40 (0.21)     6.24 (0.26) <0.001     6.56 (0.42) <0.001
Schirmer test (mm)     3.58 (0.19)     3.71 (0.23)   0.630     4.63 (0.53)   0.082
Tear osmolarity (mOsm/L) 308.95 (2.90) 307.97 (2.81)   0.771 301.46 (2.55)   0.008
TFBUT, tear film breakup time; SE, standard error.
Table 2. Changes in Inflammatory Cytokine Concentrations
Baseline (SE) pg/mL 4 wks (SE) pg/mL p value 8 wks (SE) pg/mL p value
IL-1β   2.05 (0.17)   1.97 (0.11) 0.621   1.60 (0.13) 0.041
IL-6   0.56 (0.34)   0.92 (0.55) 0.537   0.19 (0.11) 0.326
IL-8   59.62 (10.84) 35.29 (6.09) 0.074 22.16 (5.73) 0.001
IL-17   1.24 (0.49)   0.29 (0.17) 0.093   0.47 (0.20) 0.079
IFN-γ   0.36 (0.16)   0.36 (0.18) 0.987   0.19 (0.11) 0.294
TNF-α   0.11 (0.11)   0.09 (0.09) 0.903   0.12 (0.09) 0.942
MCP-1 31.97 (6.51) 28.05 (5.91) 0.558 13.30 (2.55) 0.008
IL, interleukin; IFN-γ, interferon gamma; TNF, tumor necrosis factor; MCP-1, monocyte chemotactic protein-1; SE, standard error.
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decreased at 8 weeks, but the decreases were not statistical-
ly significant (Table 2, Fig. 1).
Safety results
There were three patients whose intraocular pressures were 
elevated above 21 mm Hg at 8 weeks. Once topical methyl-
prednisolone was stopped, their intraocular pressures re-
turned to the normal range within one month follow-up. 
DISCUSSION
This study showed that the therapeutic effect of topical 1% 
methylprednisolone in the treatment of dry eye syndrome 
could be proven not only by improvements of clinical indi-
ces, but also by decreases in tear osmolarity and inflamma-
tory cytokines levels. The important findings, which cor-
roborate previous studies, are that IL-1β and IL-8 in tears 
were decreased after the treatment with steroid and that tear 
osmolarity decreases with steroid use. 
Tear hyperosmolarity is regarded as the core mechanism 
causing ocular surface inflammation in dry eye syndrome.3 
Hyperosmolarity stimulates a cascade of inflammatory 
events in the epithelial surface cells, involving mitogen-ac-
tivated protein kinases (MAPKs), the nuclear factor-kappa 
B signaling pathway,16 and the generation of inflammatory 
cytokines (IL-1α, IL-1β, and TNF-α) and MMP-9,13 which 
activate inflammatory cells at the ocular surface.17,18 In-
creased levels of multiple pro-inflammatory cytokines in 
the tears of patients with dry eye syndrome have been con-
firmed by previous studies.4-6 
Tear osmolarity is believed to be a global indicator of the 
disease3 and has been proposed as the gold standard for di-
agnosis of dry eyes.19 With technological advances, it is 
now possible to measure osmolarity using small amounts 
of tears, and more conveniently, by collecting tear samples 
from the inferior tear lake with the tip of the test card.
In this study, we intended to propose an objective approach 
to evaluate the efficacy of topical methylprednisolone in the 
treatment of patients with dry eye syndrome. Recent studies 
have shown that inflammatory cytokines and tear osmolari-
ty are increased in dry eye syndrome and that tear osmolari-
ty has a significant correlation with dry eye severity.4-8 By 
measuring changes in inflammatory cytokine levels and 
tear osmolarity, we could objectively show an anti-inflam-
matory effect of methylprednisolone in addition to clinical 
improvement.
Changes in dry eye signs and tear osmolarity
Corneal and conjunctival staining scores and TFBUT showed 
statistically significant improvement at 4 and 8 weeks com-
pared with baseline. Schirmer test scores were increased at 
4 and 8 weeks; however, there were no statistically signifi-
cant differences. A statistically significant decrease in tear 
osmolarity was observed at 8 weeks compared with base-
line (Table 1).
 
Changes in inflammatory cytokine concentrations
IL-1β, IL-8, and MCP-1 were significantly decreased at 8 
weeks compared to baseline. IL-6, IL-17, and IFN-γ also 
Fig. 1. Changes in concentration of IL-1β, IL-8, and MCP-1 before and after 
treatment. IL, interleukin; MCP-1, monocyte chemotactic protein-1.
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the improvement of dry eyes. 
Despite its therapeutic effect in the treatment of moderate 
to severe dry eye, topical methylprednisolone should be used 
for a short-term period to avoid steroid-related complications 
such as elevation of intraocular pressure and cataract. In a 
pervious study which reviewed the efficacy and side effects 
of topical nonpreserved corticosteroid therapy, there were no 
complications observed after 2 weeks of therapy; complica-
tions including elevated intraocular pressure and cataracts 
were observed after several months of therapy.10 In another 
study, which compared the efficacy of topical cyclosporine 
0.05% and combined treatment with 1% methylprednisolone 
acetate, there was no report of elevated intraocular pressure 
after 3 weeks use of topical steroid in a tapering manner.14 El-
evated intraocular pressure was detected in three patients at 8 
weeks, but was normalized after stopping the medication in 
this study. Careful follow-up examination to detect such 
complications would also be important.
As the therapeutic efficacy of topical steroid is well prov-
en in previous studies,10,11,13 we did not directly compare the 
efficacy of a topical steroid group with a sodium hyaluro-
nate group. Thus, the results of this study should be inter-
preted as an effect of topical methylprednisolone in combi-
nation with sodium hyaluronate. 
Although fluorescein is less ideal for conjunctival stain-
ing compared to rose bengal or lissamine green, we graded 
staining patterns immediately after measuring fluorescein 
tear breakup time to minimize interactions between tests 
and to limit the extent of influences of an additional test to 
the other tests that followed. 
Preservatives in topical agents such as benzalkonium chlo-
ride excite inflammatory cell markers at the ocular surface, 
causing epithelial cell damage and a decrease in mucin.3 In 
this study, topical methylprednisolone was prepared as a 
non-preserved topical solution to avoid the toxicity associ-
ated with a preservative. 
In summary, we objectively evaluated the anti-inflamma-
tory effects of topical methylprednisolone applied with non-
preserved sodium hyaluronate in the treatment of patients 
with moderate to severe dry eye syndrome and demonstrat-
ed improvements in inflammatory cytokine levels and tear 
osmolarity after treatment.
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Methylprednisolone has been shown to have great effica-
cy in preserving corneal epithelial barrier function. De Pai-
va, et al.13 reported that methylprednisolone decreased levels 
of IL-1α, IL-1β, and TNF-α transcripts as well as activation 
of MAPKs. In this study, we confirmed a significant de-
crease in IL-1β levels after treatment with topical methyl-
prednisolone. The therapeutic effect of methylprednisolone 
may be the result of indirect MAPKs inhibition by decreas-
ing the production of both IL-1 and TNF-α, MAPKs activa-
tors, as corticosteroids have not been recognized as direct 
MAPKs inhibitors.13,20
IL-17 is a potent pro-inflammatory cytokine, and interac-
tion of IL-17 with its receptor evokes activation of IL-8, re-
sulting in recruitment of neutrophils to the injury site.21 MCP-
1 has been identified as a key molecule for the chemotaxis 
of monocytes to the site of inflammation.22 The results of 
this study showed that IL-8 and MCP-1 levels were all sig-
nificantly decreased by topical methylprednisolone. These 
findings suggest that topical methylprednisolone improved 
ocular surface inflammation by decreasing the recruitment 
of inflammatory cells. Other pro-inflammatory cytokines 
including IL-6, IL-17, and IFN-γ also decreased, but the 
differences were not statistically significant in this study. 
Tear hyperosmolarity arises in situations of low aqueous 
tear flow, excessive evaporation, or a combination of these 
events.3 A previous study demonstrated that patients with 
faster tear film thinning time may be more susceptible to 
evaporation of the tear film, which may lead to a more con-
centrated tear film and increased osmolarity.23 In this study, 
tear film stability (TFBUT) was significantly improved at 4 
and 8 weeks, and tear osmolarity significantly decreased at 
8 weeks. It is possible that improved tear film stability 
slowed down tear film thinning time in patients, followed 
by decreased tear osmolarity. 
Tear osmolarity at 4 weeks also showed a decrease from 
baseline, which was not significant compared to clinical pa-
rameters such as corneal and conjunctival staining and TF-
BUT at 4 weeks. It could mean that epithelial damage and 
tear film instability were improved relatively faster than a 
decrease of tear osmolarity in this study. A recent study, 
which evaluated the efficacy of lubricant eye drops by mea-
suring tear osmolarity, also reported that lubricant eye drops 
improved TFBUT, Schirmer test values, and fluorescein 
staining grade; however, tear osmolarity did not change sig-
nificantly after 30 days of treatment.24 Further investiga-
tions would be required to evaluate the relationship between 
epithelial recovery and decrease of tear osmolarity during 
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